Clinical trial · Observational
Observational Study on Patients With Hepatobiliary Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is still high. Therefore, it is of great significance to find important prognostic markers to improve patient prognosis and formulate new treatment plans. In recent years, targeted therapy and immunotherapy make cancer treatment enter a new field, However, tumor heterogeneity is the greatest challenge in cancer therapeutics and biomarkers discovery. In this study, we collected a wide rang of patients' information, including photos of patients' face, physical strength and nutrition indicators, blood ,stool and pathological tissue specimens from tumor patients, then Multi-omics testing were applied to Looking for novel therapeutic targets and prognostic markers to predict patient response to treatment. Clinicians choose the best treatment plan for the patient based on the test results to improve the patient's survival time and quality of life.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Cancer | Malignant Biliary Tract Neoplasm | ALIAS | 0.90 |
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Gallbladder Cancer | Malignant Gallbladder Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evaluate the overall survival rate of all patients with hepatobiliary tumor
- timeFrame
- 5 years
- description
- In order to identify the potential influence factors of hepatobiliary tumor patients survival
Secondary outcomes (3)
- measure
- Evaluate the recurrence free survival rate of patients with hepatobiliary tumor
- timeFrame
- 5 years
- description
- In order to identify the potential influence factors of tumor recurrencesamples from patients with hepatobiliary cancers
- measure
- Evaluate the cancer-specific survival rate of patients with hepatobiliary tumor
- timeFrame
- 5 years
- description
- In order to identify the potential influence factors of tumor-induced death in patients with hepatobiliary tumors
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Be older than 18 years old; 2. Clinical or pathological diagnosis of malignant hepatobiliary tumors; 3. Patients have received or are about to receive surgery, chemotherapy radiotherapy, targeted therapy, local therapy, immunotherapy, etc; 4. Patients understand and are willing to sign written informed consent. Exclusion Criteria: 1. Patients considered by the doctor to be unsuitable for entry into this study (mental disorder or poor compliance, etc.); 2. The patient or guardian is unwilling to participate in this study; 3. Pregnant women; 4. Combined with other serious systemic diseases (heart failure, renal failure,hematopoietic system disease or Uncontrollable acute infection); 5. Estimated survival time is less than 1 month.
References
Publications (1)
- DERIVEDYang J, Wang D, Ma L, An X, Hu Z, Zhu H, Zhang W, Chen K, Ma J, Yang Y, Wu L, Chen G, Wang Y. Sarcopenia negatively affects postoperative short-term outcomes of patients with non-cirrhosis liver cancer. BMC Cancer. 2023 Mar 6;23(1):212. doi: 10.1186/s12885-023-10643-6. PMID 36879265